Acute and chronic optic nerve head biomechanics and intraocular pressure changes in patients receiving multiple intravitreal injections of anti-VEGF

  • M. Gómez-MariscalEmail author
  • B. Puerto
  • F. J. Muñoz-Negrete
  • V. de Juan
  • G. Rebolleda



To evaluate acute and chronic changes in optic nerve head (ONH) structures and intraocular pressure (IOP) in patients receiving intravitreal injections (IVIs) of anti-VEGF.


Twenty-nine eyes receiving IVIs for the first time were studied. IOP, retinal nerve fiber layer (RNFL) thickness, and ONH structures were evaluated by Spectralis optical coherence tomography with enhanced depth imaging technology. Structures were measured before and 5 min after each one of the three monthly injections of a loading dose treatment. In 13 eyes (44.8%) with more than six IVIs, another evaluation pre and immediately postinjection was performed after 1 year.


A significant acute and transient IOP increase (all p ≤ 0.001), Bruch’s membrane opening (BMO) enlargement (p ≤ 0.001), cup widening (p < 0.05) and deepening (p ≤ 0.001), and prelaminar tissue thinning (p ≤ 0.001) were observed 5 min after each injection. Compared with baseline values, a significant BMO expansion (p = 0.001) and RNFL thinning (p < 0.001) were observed in the third month. In eyes with more than six IVIs, similar immediate postinjection changes, including IOP increase (p = 0.001), prelaminar tissue thinning (p = 0.007), and cup deepening (p = 0.012) were observed at 1 year, while BMO expansion was not significant (p = 0.556). Compared with baseline preinjection values, a significant BMO expansion (p = 0.003), prelaminar tissue thinning (p = 0.011), and cup deepening (p = 0.006) in the inferior region of the ONH occurred. No change in IOP was observed at the end of follow-up.


Repeated IVIs could lead to irreversible changes in ONH structures. Large-scale, prospective studies are required to determine the long-term effects of anti-VEGF treatments in ONH tissues.


Optic nerve head Lamina cribrosa Intraocular pressure Intravitreal injection Retinal nerve fiber layer Enhanced depth imaging 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in the current study were in accordance with the ethical standards of Institutional Research Ethics Committee of Ramón y Cajal University Hospital and with the tenets of 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Schlingemann R, Witmer A (2009) Treatment of retinal diseases with VEGF antagonists. Prog Brain Res 175:253–267. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Falkenstein I, Cheng L, Freeman W (2007) Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 27:1044–1047CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kim J, Mantravadi A, Hur E, Covert D (2008) Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 146:930–934. CrossRefGoogle Scholar
  4. 4.
    Bakri S, Pulido J, McCannel C et al (2009) Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye 23:181–185CrossRefGoogle Scholar
  5. 5.
    Kotliar K, Maier M, Bauer S, Al E (2007) Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 85:777–781CrossRefGoogle Scholar
  6. 6.
    Rebolleda G, Puerto B, de Juan V et al (2016) Optic nerve head biomechanic and IOP changes before and after the injection of aflibercept for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 57:5688–5695. CrossRefGoogle Scholar
  7. 7.
    Bakri S, McCannel C, Edwards A, Moshfeghi D (2008) Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 246:955–958. CrossRefPubMedGoogle Scholar
  8. 8.
    Adelman R, Zheng Q, Mayer H (2010) Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 26:105–110. CrossRefPubMedGoogle Scholar
  9. 9.
    Good T, Kimura A, Mandava N, Kahook M (2011) Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 95:1111–1114. CrossRefPubMedGoogle Scholar
  10. 10.
    Mathalone N, Arodi-Golan A, Sar S, Al E (2012) Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 250:1435–1440. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Tseng J, Vance S, Della Torre K, Al E (2012) Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 21:241–247. CrossRefGoogle Scholar
  12. 12.
    Bakri S, Moshfeghi D, Francom S et al (2014) Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. Ophthalmology 121:1102. CrossRefGoogle Scholar
  13. 13.
    Eadie B, Etminan M, Carleton B et al (2017) Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery. JAMA Ophthalmol 135:363–368. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Atchison E, Wood K, Mattox C et al (2018) The real-world effect of intravitreous anti-vascular endothelial growth factor drugs on intraocular pressure: an analysis using the IRIS registry. Ophthalmology 125:676–682. CrossRefGoogle Scholar
  15. 15.
    Lee E, Kim T, Weinreb R et al (2011) Visualization of the lamina cribrosa using enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 152:87–95. CrossRefGoogle Scholar
  16. 16.
    Liu J, He X (2009) Corneal stiffness affects IOP elevation during rapid volume change in the eye. Invest Ophthalmol Vis Sci 50:2224–2229. CrossRefGoogle Scholar
  17. 17.
    Morris H, Tang J, Cruz Perez B et al (2013) Correlation between biomechanical responses of posterior sclera and IOP elevations during micro intraocular volume change. Invest Ophthalmol Vis Sci 54:7215–7222. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Sigal I, Grimm J, Jan N et al (2014) Eye-specific IOP-induced displacements and deformations of human lamina cribrosa. Invest Ophthalmol Vis Sci 55:1–15. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Downs J, Roberts M, Burgoyne C (2008) Mechanical environment of the optic nerve head in glaucoma. Optom Vis Sci 85:425–435. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Shelton L, Rada J (2007) Effects of cyclic mechanical stretch on extracellular matrix synthesis by human scleral fibroblasts. Exp Eye Res 84:314–322CrossRefPubMedGoogle Scholar
  21. 21.
    Wang G, Chen W (2012) Effects of mechanical stimulation on viscoelasticity of rabbit scleral fibroblasts after posterior scleral reinforcement. Exp Biol Med 237:1150–1154. CrossRefGoogle Scholar
  22. 22.
    Goktas A, Goktas S, Atas M et al (2013) Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure. Cutan Ocul Toxicol 32:23–26. CrossRefPubMedGoogle Scholar
  23. 23.
    Gismondi M, Salati C, Salvetat M et al (2009) Short term effect of intravitreal injection of ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 18:658–661. CrossRefPubMedGoogle Scholar
  24. 24.
    Menzel C, Kotliar K, Lanzl I (2009) Retrospective investigation of seasonal factors influencing intraocular pressure in glaucoma patients. Ophthalmologe 106:1006–1011. CrossRefPubMedGoogle Scholar
  25. 25.
    Qureshi I, Xiao R, Yang B et al (1999) Seasonal and diurnal variations of ocular pressure in ocular hypertensive subjects in Pakistan. Singap Med J 40:345–348Google Scholar
  26. 26.
    Cacciamani A, Oddone F, Parravano M et al (2013) Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. Jpn J Ophthalmol 57:63–67. CrossRefPubMedGoogle Scholar
  27. 27.
    Radius R (1981) Regional specificity in anatomy at the lamina cribrosa. Arch Ophthalmol 99:478–480CrossRefPubMedGoogle Scholar
  28. 28.
    Quigley H, Addicks E (1981) Regional differences in the structure of the lamina cribrosa and their relation to glaucomatous optic nerve damage. Arch Ophthalmol 99:137–143CrossRefPubMedGoogle Scholar
  29. 29.
    Winkler M, Jester B, Nien-Shy C et al (2010) High resolution three-dimensional reconstruction of the collagenous matrix of the human optic nerve head. Brain Res Bull 81:339–348CrossRefPubMedGoogle Scholar
  30. 30.
    Roberts M, Liang Y, Sigal I, Al E (2010) Correlation between local stress and strain and lamina cribrosa connective tissue volume fraction in normal monkey eyes. Invest Ophthalmol Vis Sci 51:295–307. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Bracha P, Moore N, Ciulla T et al (2018) The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: a review. Surv Ophthalmol 63:281–295. CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Hoguet A, Chen P, Junk A et al (2019) The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the american academy of ophthalmology. Ophthalmology 126:611–622. CrossRefGoogle Scholar
  33. 33.
    Shin H, Kim S, Chung H et al (2016) Intravitreal anti-vascular endothelial growth factor therapy and retinal nerve fiber layer loss in eyes with age-related macular degeneration: a meta-analysis. Invest Ophthalmol Vis Sci 57:1798–1806. CrossRefGoogle Scholar
  34. 34.
    Soheilian M, Karimi S, Montahae T et al (2017) Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study. Graefes Arch Clin Exp Ophthalmol 255:1705–1712. CrossRefGoogle Scholar
  35. 35.
    Martinez-de-la-Casa J, Ruiz-Calvo A, Saenz-Frances F et al (2012) Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci 53:6214–6218. CrossRefGoogle Scholar
  36. 36.
    Horsley M, Mandava N, Maycotte M, Kahook M (2010) Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol 150:558–561. CrossRefGoogle Scholar
  37. 37.
    Shin H, Shin K, Chung H, Kim H (2014) Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor. Invest Ophthalmol Vis Sci 55:2403–2411. CrossRefGoogle Scholar
  38. 38.
    Zucchiatti I, Cicinelli M, Parodi M et al (2017) Effect of intravitreal ranibizumab on ganglion cell complex and peripapillary retinal nerve fiber layer in neovascular age-related macular degeneration using spectral domain optical coherence tomography. Retina 37:1314–1319. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Hospital Universitario Ramón y CajalUniversidad de AlcaláMadridSpain
  2. 2.Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)Hospital Universitario Ramón y CajalMadridSpain

Personalised recommendations